Integrated Diagnostics this week said it has launched a new operating division called InDi Imaging to commercialize PET imaging probes based on its protein catalyzed capture agent, or PCC, technology.

The company announced that it has appointed Norman Hardman president of the new division and appointed University of California, Los Angeles professor Michael Phelps, the inventor of PET, to the division as an advisor. It also said that it planned to start the first human studies of the PCC-based PET imaging reagents over the next 12 to 18 months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.